Developer docs
API playgroundTry for free, no card

Search company profiles

Biom'Up

Full company profile

uuid0005qvb

Namestring
Biom'Up
Websiteurl
biomup.com
Company typeenum
Private
Founded yearint
2005
Short descriptiontext

Biom'Up is a French specialty medical device company founded in 2005 that designs and manufactures resorbable collagen-based hemostatic products for surgical bleeding control and postpartum hemorrhage applications. The firm has been delisted and currently lacks an active corporate web presence.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersSaint-priest-ligoure, France
HQ citystring
Saint-priest-ligoure
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Keyword5 values
biodegradable hemostats, collagen medical devices, surgical hemostatic products, resorbable surgical devices, postpartum hemorrhage solutions
Industry1 code
PRIMARYIMAEAOAL
Biodegradable Medical & Hygiene Materials (absorbables, disposables substrates)
NAICS code2 codes
  • Surgical Appliance and Supplies Manufacturing339113
  • Medical Equipment and Supplies Manufacturing33911
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Surgical Hemostats
Social media profiles2 records
Cost components5 values
Personnel, Supply Chain, Operations, Technology or R&D, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Biom'Up is a French medical device manufacturer that develops and produces re-absorbable surgical devices based on proprietary collagen technology. The company's core focus is on biodegradable hemostatic products designed for surgical bleeding control and postpartum hemorrhage management, operating within the broader biomaterials and surgical hemostat market.

Differentiator
Functional benefit
Problem solved
Scale indicator1 record

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierNot SpecifiedTypeOthersAnnounced on2023-03-01
Description

In March 2023, UK-based Medtrade Products Ltd partnered with Swiss company Laubscher and Co AG to introduce CELOX PPH uterine haemostatic tamponade solution for addressing postpartum hemorrhage in Switzerland. This represents activity in the broader hemostat market that Biom'Up participates in.

Peers10 records
1CryoLife
TypeDirect peer
Description

CryoLife (now part of Artivion) develops surgical sealants and hemostats used in cardiac and vascular surgery. Its BioGlue and related surgical adhesive/hemostatic products compete directly with Biom'Up's absorbable hemostatic devices in operating-room settings.

TypeBroad incumbent
Description

Integra LifeSciences offers a portfolio of hemostatic agents, dural repair, and surgical products, including collagen-based absorbable hemostats. It serves as a broader incumbent competing in the same surgical hemostasis and tissue management space.

TypeDirect peer
Description

Baxter is a leading manufacturer of surgical hemostats and sealants, most notably FLOSEAL (a gelatin matrix hemostatic sealant) and TISSEEL (fibrin sealant). Its gelatin-based FLOSEAL is highly comparable to Biom'Up's collagen-based absorbable hemostats in indication and surgical setting.

TypeDirect peer
Description

Medtrade Products makes CELOX hemostatic gauze and the CELOX PPH uterine tamponade for postpartum hemorrhage. Both companies compete in the biodegradable/absorbable hemostat category, with overlapping indications in surgical and obstetric bleeding control.

TypeBroad incumbent
Description

BD is a diversified medical device incumbent with a portfolio that includes hemostatic products and surgical adjuncts. Its scale, regulatory resources, and global commercial reach make it a key competitive force in surgical hemostasis alongside Biom'Up's niche offerings.

TypeDirect peer
Description

Ethicon is a market-leading surgical hemostat and sealant franchise (SURGIFLO Hemostatic Matrix, EVICEL Fibrin Sealant). Its absorbable, flowable hemostatic matrix products directly compete with Biom'Up's collagen-based offering in the same surgical bleeding-control category.

TypeEmerging player
Description

Marine Polymer Technologies develops poly-N-acetyl glucosamine (pGlcNAc)-based hemostatic devices (SyvekPatch, Rapid Deployment Hemostat). As a smaller specialist with biomaterial-based hemostats, it is comparable to Biom'Up in scale and technology approach.

TypeEmerging player
Description

Z-Medica, now part of Teleflex, markets QuikClot hemostatic gauze and kaolin-based hemostatic agents used in surgical and trauma settings. It competes in the same absorbable/kaolin-based hemostat category with overlapping indications.

TypeEmerging player
Description

Advanced Medical Solutions develops and commercializes absorbable hemostats, sealants, and tissue adhesives (e.g., LiquiBand, ActivHeal). As a UK-based specialist with comparable size and focus, it is a relevant emerging competitor and potential comparable for Biom'Up.

TypeEmerging player
Description

CorMatrix developed ECM (extracellular matrix) biomaterial-based absorbable implants for cardiac and vascular surgery. Its collagen/ECM-based absorbable technology platform is thematically comparable to Biom'Up's collagen-based re-absorbable medical device approach.

Market position
Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors9 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Biom'Up

Surgical Hemostatsbiomup.com

Biom'Up is a French specialty medical device company founded in 2005 that designs and manufactures resorbable collagen-based hemostatic products for surgical bleeding control and postpartum hemorrhage applications. The firm has been delisted and currently lacks an active corporate web presence.

Biom'Up firmographics

Firmographics
Name
Biom'Up
Website
https://biomup.com
Company type
Private
Founded year
2005
Operating status
Operating
Headcount range
1–10 employees
Short description
Biom'Up is a French specialty medical device company founded in 2005 that designs and manufactures resorbable collagen-based hemostatic products for surgical bleeding control and postpartum hemorrhage applications. The firm has been delisted and currently lacks an active corporate web presence.
Ownership category
akta.pro rank

Biom'Up industry classification

Industry
Product category
Surgical Hemostats
NAICS
Surgical Appliance and Supplies Manufacturing (339113), Medical Equipment and Supplies Manufacturing (33911)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYIMAEAOAL
Biodegradable Medical & Hygiene Materials (absorbables, disposables substrates)

Keywords

  • Biodegradable hemostats
  • Collagen medical devices
  • Surgical hemostatic products
  • Resorbable surgical devices
  • Postpartum hemorrhage solutions

Where Biom'Up is headquartered

Location

Headquarters

HQ city
Saint-priest-ligoure
HQ country
France
HQ region
Europe

Markets served

Biom'Up business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Supply Chain, Operations, Technology or R&D, Marketing or Sales

Biom'Up product offering

Product offering

Core offering

Biom'Up is a French medical device manufacturer that develops and produces re-absorbable surgical devices based on proprietary collagen technology. The company's core focus is on biodegradable hemostatic products designed for surgical bleeding control and postpartum hemorrhage management, operating within the broader biomaterials and surgical hemostat market.

Differentiator

Problem solved

Functional benefit

Companies that use Biom'Up

Customer profile

Ideal customer profiles1 record

Biom'Up technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Biom'Up partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Medtrade Products Ltdnot specifiedOthers · 1 March 2023In March 2023, UK-based Medtrade Products Ltd partnered with Swiss company Laubscher and Co AG to introduce CELOX PPH uterine haemostatic tamponade solution for addressing postpartum hemorrhage in Switzerland. This represents activity in the broader hemostat market that Biom'Up participates in.

Scale indicators1 record

Biom'Up competitors and assessment

Company assessment

Direct peers

  • CryoLife: CryoLife (now part of Artivion) develops surgical sealants and hemostats used in cardiac and vascular surgery. Its BioGlue and related surgical adhesive/hemostatic products compete directly with Biom'Up's absorbable hemostatic devices in operating-room settings.
  • Baxter International: Baxter is a leading manufacturer of surgical hemostats and sealants, most notably FLOSEAL (a gelatin matrix hemostatic sealant) and TISSEEL (fibrin sealant). Its gelatin-based FLOSEAL is highly comparable to Biom'Up's collagen-based absorbable hemostats in indication and surgical setting.
  • Medtrade Products: Medtrade Products makes CELOX hemostatic gauze and the CELOX PPH uterine tamponade for postpartum hemorrhage. Both companies compete in the biodegradable/absorbable hemostat category, with overlapping indications in surgical and obstetric bleeding control.
  • Ethicon (Johnson & Johnson): Ethicon is a market-leading surgical hemostat and sealant franchise (SURGIFLO Hemostatic Matrix, EVICEL Fibrin Sealant). Its absorbable, flowable hemostatic matrix products directly compete with Biom'Up's collagen-based offering in the same surgical bleeding-control category.

Broad incumbents

  • Integra LifeSciences: Integra LifeSciences offers a portfolio of hemostatic agents, dural repair, and surgical products, including collagen-based absorbable hemostats. It serves as a broader incumbent competing in the same surgical hemostasis and tissue management space.
  • Becton Dickinson (BD): BD is a diversified medical device incumbent with a portfolio that includes hemostatic products and surgical adjuncts. Its scale, regulatory resources, and global commercial reach make it a key competitive force in surgical hemostasis alongside Biom'Up's niche offerings.

Emerging players

  • Marine Polymer Technologies: Marine Polymer Technologies develops poly-N-acetyl glucosamine (pGlcNAc)-based hemostatic devices (SyvekPatch, Rapid Deployment Hemostat). As a smaller specialist with biomaterial-based hemostats, it is comparable to Biom'Up in scale and technology approach.
  • Z-Medica (QuikClot): Z-Medica, now part of Teleflex, markets QuikClot hemostatic gauze and kaolin-based hemostatic agents used in surgical and trauma settings. It competes in the same absorbable/kaolin-based hemostat category with overlapping indications.
  • Advanced Medical Solutions: Advanced Medical Solutions develops and commercializes absorbable hemostats, sealants, and tissue adhesives (e.g., LiquiBand, ActivHeal). As a UK-based specialist with comparable size and focus, it is a relevant emerging competitor and potential comparable for Biom'Up.
  • CorMatrix Cardiovascular: CorMatrix developed ECM (extracellular matrix) biomaterial-based absorbable implants for cardiac and vascular surgery. Its collagen/ECM-based absorbable technology platform is thematically comparable to Biom'Up's collagen-based re-absorbable medical device approach.

Market position

Customer concentration

Biom'Up social profiles

Digital presence

Biom'Up financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Biom'Up leadership team

Management profile

Number of profiles

Profiles5 records

Biom'Up funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Biom'Up M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Biom'Up

What does Biom'Up do?

Biom'Up is a French medical device manufacturer that develops and produces re-absorbable surgical devices based on proprietary collagen technology. The company's core focus is on biodegradable hemostatic products designed for surgical bleeding control and postpartum hemorrhage management, operating within the broader biomaterials and surgical hemostat market.

When was Biom'Up founded?

Biom'Up was founded in 2005. It employs 1 to 10 people.

Where is Biom'Up based?

Biom'Up is headquartered in Saint-priest-ligoure, France, in the Europe region.

Who are Biom'Up's main competitors?

Direct peers on record are CryoLife, Baxter International, Medtrade Products and Ethicon (Johnson & Johnson). Broad incumbents are Integra LifeSciences and Becton Dickinson (BD). Emerging players are Marine Polymer Technologies, Z-Medica (QuikClot), Advanced Medical Solutions and CorMatrix Cardiovascular.

Does Biom'Up have an API?

No public API is recorded for Biom'Up.

What industry is Biom'Up in?

Biom'Up's product category is Surgical Hemostats. Its primary akta.pro industry code is IMAEAOAL, Biodegradable Medical & Hygiene Materials (absorbables, disposables substrates). Its NAICS code is 339113 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireRenowned Hemostat Innovator Joins Medcura to Drive Clinical Studies, Regulatory PursuitsMedcura, Inc. appointed Rachel Hoffman as Senior Vice President of Clinical and Regulatory Affairs to lead clinical studies and regulatory applications for its hemostatic technologies. This leadership addition supports the company's upcoming human trials for LifeGel™ Absorbable Surgical Hemostat and pre-clinical testing for other products like LifeFoam™. Hoffman brings extensive experience from previous roles at Syneos Health and Biom'up to drive these developmental milestones.PR NewswireBiom'up Australian Market Growth Gathers PaceBiom'up France SAS has reported strong growth traction in the Australian market for its HEMOBLAST Bellows hemostatic product following its launch in July 2020, with positive feedback from Australian surgeons. The company distributes the product through an exclusive agreement with LifeHealthcare, covering Australia and New Zealand, with TGA ARTG inclusion confirmed in May 2020. The Australian hemostat market is valued at $59M AUD, of which $35M is addressable for combination hemostats.GlobeNewswireBiom’up Finalizes U.S. Commercial Organization to Support U.S. Launch of HEMOBLAST™ BellowsBiom'up finalized its U.S. commercial organization to support the mid-2018 launch of HEMOBLAST Bellows, recruiting over 100 specialist sales representatives. The company obtained FDA approval in December 2017, seven months ahead of schedule, and expects the product to become a fixture in U.S. operating rooms.GlobeNewswireBiom’up Has Trained 200 Surgeons in its International KOL-Led Program Ahead of HEMOBLAST Bellows™ LaunchBiom'up announced it has trained 200 surgeons in its HEMOBLAST Bellows program ahead of the product's mid-2018 launch. The company held six training sessions and plans more boot camps to drive adoption. The product received FDA approval in December 2017, seven months ahead of schedule.GlobeNewswireBiom'up reports 2017 full-year results and provides corporate updateBiom'up reported 2017 full-year results, raising €100 million through 2017, and obtained FDA marketing approval for HEMOBLAST Bellows in December 2017, seven months ahead of schedule. The company plans to launch the product in mid-2018 and build a new manufacturing facility by 2020.GlobeNewswireBiom’up Appoints Thierry Darnis as Global Vice President, Manufacturing & EngineeringBiom'up appointed Thierry Darnis as Global Vice President Manufacturing and Engineering, effective May 2, 2018. He will oversee production scale-up for HEMOBLAST Bellows and a new plant planned for 2020. The appointment supports the company's growth strategy.FinSMEsBiom’Up Secures €31.3M in Series C FinancingBiom’Up, a French collagen-based medical device company, raised €31.3M in Series C financing from Gimv, Bpifrance Large Venture, and Lundbeckfond Ventures. The funds will support development of HEMOBLAST, with a clinical study in Europe and North America. The company expects over 30% sales growth in 2015.FinSMEsBiom’Up Raises €6.8M in FundingBiom'Up, a French re-absorbable medical device maker, raised €6.8M from existing and new investors. The funds will support a sales team expansion, a phase III clinical trial in Europe and the US, and FDA 510(k) filings for new products.